Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC-007 in Healthy Subjects and Overweight or Obese Subjects
NCT07102251Phase 1Recruiting
- Sponsor
- Sunshine Lake Pharma
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Modified Peptides, Native Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HEC-007 in obesity and Overweight (4 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Adverse events, Maximum plasma concentration and 10 more. Started Sep 2025; status: recruiting.
02
Drugs
HEC-007
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07102251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07102251.